Zoetis Inc. $ZTS Shares Sold by Groupama Asset Managment

Groupama Asset Managment reduced its position in Zoetis Inc. (NYSE:ZTS) by 23.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,481 shares of the company’s stock after selling 2,021 shares during the period. Groupama Asset Managment’s holdings in Zoetis were worth $1,057,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares in the last quarter. Polen Capital Management LLC lifted its stake in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after purchasing an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after purchasing an additional 109,791 shares in the last quarter. Finally, Unisphere Establishment lifted its stake in shares of Zoetis by 7.3% in the 4th quarter. Unisphere Establishment now owns 4,800,000 shares of the company’s stock valued at $782,064,000 after purchasing an additional 325,000 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS stock opened at $156.6940 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock’s 50 day moving average is $154.27 and its two-hundred day moving average is $158.86. The company has a market capitalization of $69.44 billion, a PE ratio of 26.97, a P/E/G ratio of 2.50 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the business earned $1.56 EPS. Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on ZTS. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.